عرض بسيط للتسجيلة

المؤلفAlalawneh, Majdoleen
المؤلفRachid, Ousama
المؤلفAbdallah, Ibtihal
المؤلفMahfouz, Ahmed
المؤلفElewa, Hazem
المؤلفDanjuma, Mohammed Ibn-Mas'ud
المؤلفMohamed, Asmaa Ezzeldin
المؤلفAwaisu, Ahmed
تاريخ الإتاحة2023-12-28T05:14:42Z
تاريخ النشر2023
اسم المنشورEuropean Journal of Clinical Pharmacology
المصدرScopus
الرقم المعياري الدولي للكتاب316970
معرّف المصادر الموحدhttp://dx.doi.org/10.1007/s00228-023-03572-7
معرّف المصادر الموحدhttp://hdl.handle.net/10576/50637
الملخصPurpose To investigate real-world prescribing trends and clinical outcomes based on body mass index (BMI) categorization in patients who received rivaroxaban therapy. Methods This was a retrospective cohort study involving all patients who received rivaroxaban therapy across all Hamad Medical Corporation (HMC) hospitals from 2015 to 2020. Results The number of patients initiated on rivaroxaban therapy significantly increased from 152 (3.3%) in 2015 to 1342 (28.9%) in 2020 (p <0.001). Within BMI categories, a similar increasing trend was observed in underweight, normal, and overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban prescribing in all obese classes. The prevalence rate of all-cause mortality differed significantly between the BMI groups, with the highest mortality being among morbidly obese patients (BMI ≥ 40 kg/m2) (p< 0.001). On the other hand, no significant differences were found between the BMI groups in terms of bleeding, pulmonary embolism, deep vein thrombosis and stroke incidences. Multivariate logistic regression analyses showed that the likelihood of all-cause mortality was significantly higher in overweight and all categories of obese patients compared to underweight patients: overweight (OR: 5.3, 95% CI: 2.3–11.9, p< 0.001); obese class 1 (OR: 5.4, 95% CI: 2.3 – 12.2, p< 0.001); obese class 2 (OR: 6.5, 95% CI: 2.7 – 15.6, p< 0.001); and obese class 3 (OR: 3.7, 95% CI: 1.6 – 8.7, p = 0.003). Conclusions Rivaroxaban prescribing has significantly increased over the years across general population, with a noticeable decline in obese population during the last few years (from 2018 onwards). Furthermore, an appreciable association was evident between all-cause mortality and BMI of these patients.
راعي المشروعThe study protocol and other associated study documents were approved by the HMC's Medical Research Centre (MRC-01-22-102) and the Institutional Review Board (IRB) at Qatar University before study initiation (QU-IRB1743-E/22).
اللغةen
الناشرSpringer Science and Business Media Deutschland GmbH
الموضوعBody mass index
Clinical outcomes
Direct oral anticoagulants
Obese
Rivaroxaban
Acute scrotum
Testicular torsion
Torsion of the appendix testis
Children
العنوانTrends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data
النوعArticle
الصفحات1675-1685
رقم العدد12
رقم المجلد79
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة